Quantification of the completeness of follow-up

Lancet

Volumn 359, Issue 9314, 2002, Pages 1309-1310

  Clark, Taane G ^a   Altman, Douglas G ^a   De Stavola, Bianca L ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MELPHALAN; PLACEBO; PREDNISONE; VINCRISTINE;

ARTICLE; CALCULATION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; OVARY CARCINOMA; PATIENT COMPLIANCE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; SAMPLE SIZE; SURVIVAL;

EID: 0037070807     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)08272-7     Document Type: Article

References (5)

1. A note on quantifying follow-up in studies of failure time
2. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials
3. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis
4. 2 microglobulin in myelomatosis
5. A prognostic model in ovarian cancer